Randomized comparison between sentinel lymph node mapping using indocyanine green plus a fluorescent camera versus lymph node dissection in clinical stage I-II endometrial cancer: a Korean Gynecologic Oncology Group trial (KGOG2029/SELYE)

Jeong-Yeol Park, Ju-Hyun Kim, Min-Hyun Baek, Eunhyang Park, Sang Wun Kim, Jeong-Yeol Park, Ju-Hyun Kim, Min-Hyun Baek, Eunhyang Park, Sang Wun Kim

Abstract

Background: Sentinel lymph node (SLN) mapping has been suggested as an alternative surgical technique to full lymphadenectomy for early-stage endometrial cancer. However, the survival outcomes of SLN mapping compared with lymphadenectomy have not been established via a prospective study.

Methods: A multi-center, single-blind, randomized controlled trial has been designed to determine the prognostic value of SLN mapping alone compared with conventional lymphadenectomy for patients with clinical stage I-II endometrial cancer. Eligible participants will be randomly assigned in a 1:1 ratio between the group to undergo SLN mapping using indocyanine green and the conventional lymph node dissection group. A high-risk group will undergo a 2-step SLN mapping procedure. The primary endpoint is the 3-year disease-free survival (DFS). The secondary endpoints are 3-year overall survival (OS), 5-year DFS, 5-year OS after surgery, pattern of recurrence, immediate surgical outcomes, success rate of SLN mapping, postoperative lymph-related complications, postoperative quality of life, and postoperative cost effectiveness. The role of pathologic ultrastaging of SLNs will also be assessed.

Trial registration: ClinicalTrials.gov Identifier (NCT number): NCT04845828.

Keywords: Endometrial Cancer; Indocyanine Green; Lymphadenectomy; Prognosis; Sentinel Lymph Node.

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

© 2022. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.

Figures

Fig. 1. Trial schema.
Fig. 1. Trial schema.
BSO, bilateral salpingo-oophorectomy; FIGO, International Federation of Obstetrics and Gynecology; LND, lymph node dissection; SLN, sentinel lymph node; TH, total hysterectomy.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
    1. Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chon HS, Chu C, et al. Uterine neoplasm, version 2.2020, NCCN clinical practice guidelines in oncology. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2020.
    1. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK ASTEC Study Group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373:125–136.
    1. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–1716.
    1. Bae HS, Lim MC, Lee JS, Lee Y, Nam BH, Seo SS, et al. Postoperative lower extremity edema in patients with primary endometrial cancer. Ann Surg Oncol. 2016;23:186–195.
    1. Ballester M, Dubernard G, Lécuru F, Heitz D, Mathevet P, Marret H, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO) Lancet Oncol. 2011;12:469–476.
    1. Balaya V, Guani B, Morice P, Querleu D, Fourchotte V, Leblanc E, et al. Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: a post-hoc analysis of SENTICOL I and SENTICOL II cohorts. Gynecol Oncol. 2021;164:53–61.
    1. Frumovitz M, Plante M, Lee PS, Sandadi S, Lilja JF, Escobar PF, et al. Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncol. 2018;19:1394–1403.
    1. Hagen B, Valla M, Aune G, Ravlo M, Abusland AB, Araya E, et al. Indocyanine green fluorescence imaging of lymph nodes during robotic-assisted laparoscopic operation for endometrial cancer. A prospective validation study using a sentinel lymph node surgical algorithm. Gynecol Oncol. 2016;143:479–483.
    1. Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol. 2019;37:1810–1818.
    1. Eoh KJ, Lee YJ, Kim HS, Lee JY, Nam EJ, Kim S, et al. Two-step sentinel lymph node mapping strategy in endometrial cancer staging using fluorescent imaging: a novel sentinel lymph node tracer injection procedure. Surg Oncol. 2018;27:514–519.
    1. Korean Gynecologic Oncology Group. Surgical manual for gynecologic oncology [Internet] Seoul: Korean Gynecologic Oncology Group; 2016. [cited 2022 May 16]. Available from: .
    1. Korean Society of Gynecologic Oncology. Practice guideline for uterine corpus cancer [Internet] Seoul: Korean Society of Gynecologic Oncology; 2020. [cited 2022 May 16]. Available from: .
    1. Guan J, Xue Y, Zang RY, Liu JH, Zhu JQ, Zheng Y, et al. Sentinel lymph Node mapping versus systematic pelvic lymphadenectomy on the prognosis for patients with intermediate-high-risk Endometrial Cancer confined to the uterus before surgery: trial protocol for a non-inferiority randomized controlled trial (SNEC trial) J Gynecol Oncol. 2021;32:e60.
    1. Obermair A, Nicklin J, Gebski V, Hayes SC, Graves N, Mileshkin L, et al. A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer - ENDO-3: ANZGOG trial 1911/2020. Int J Gynecol Cancer. 2021;31:1595–1601.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する